JRCT ID: jRCT2080224595
Registered date:14/03/2019
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 25/03/2019 |
Target sample size | 1037 |
Countries of recruitment | Japan,Asia except Japan,North America,South America,Europe,Oceania,Africa |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : Talazoparib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Enzalutamide Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : --- Other Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Enzalutamide Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | confirmatory efficacy |
---|---|
Secondary Outcome | safety efficacy confirmatory exploratory pharmacokinetics |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Male |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT03395197,JapicCTI-194665 |
Contact
Public contact | |
Name | |
Address | |
Telephone | - |
clinical-trials@pfizer.com | |
Affiliation | |
Scientific contact | |
Name | |
Address | |
Telephone | - |
clinical-trials@pfizer.com | |
Affiliation |